Literature DB >> 17190528

Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations.

Philip Hazell1.   

Abstract

Approximately one-half of children medicated for attention-deficit hyperactivity disorder (ADHD) will continue to experience sufficient impairment during adolescence to warrant the continuation of their treatment; a smaller number of people with ADHD may require treatment for the first time during adolescence. The academic and social demands of adolescence can exaggerate the impairment caused by attentional problems, as adolescents, more so than children, have activities in the afternoon and evening that will tax their attentional abilities. Stimulant and nonstimulant medications are likely to be as effective for adolescent patients as they are for younger children, provided treatment adherence is satisfactory. Long-acting medications are preferred over immediate-release compounds as they provide better coverage of symptoms throughout the day. Patterns of comorbidity with ADHD change from childhood to adolescence and may require a shift in treatment strategy. The choice of time to discontinue treatment should be a decision shared by the clinician and the patient. A negotiated trial of time off treatment followed by a review of the patient's symptoms can avert premature discontinuation of treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17190528     DOI: 10.2165/00023210-200721010-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  52 in total

1.  Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  H Gutgesell; D Atkins; R Barst; M Buck; W Franklin; R Humes; R Ringel; R Shaddy; K A Taubert
Journal:  Circulation       Date:  1999-02-23       Impact factor: 29.690

2.  Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders.

Authors:  Mina Hah; Kiki Chang
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-12       Impact factor: 2.576

3.  The relationship between cannabis and violence: a review.

Authors:  E L Abel
Journal:  Psychol Bull       Date:  1977-03       Impact factor: 17.737

Review 4.  Extended-release methylphenidate (Ritalin LA).

Authors:  Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD).

Authors:  B H Smith; D A Waschbusch; M T Willoughby; S Evans
Journal:  Clin Child Fam Psychol Rev       Date:  2000-12

6.  Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders.

Authors:  Ramon Solhkhah; Timothy E Wilens; Jeanine Daly; Jefferson B Prince; Stephanie L Van Patten; Joseph Biederman
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-10       Impact factor: 2.576

7.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Authors:  Laurence L Greenhill; Robert L Findling; James M Swanson
Journal:  Pediatrics       Date:  2002-03       Impact factor: 7.124

8.  Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.

Authors:  Russell E Scheffer; Robert A Kowatch; Thomas Carmody; A John Rush
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

9.  Time trends in adolescent mental health.

Authors:  Stephan Collishaw; Barbara Maughan; Robert Goodman; Andrew Pickles
Journal:  J Child Psychol Psychiatry       Date:  2004-11       Impact factor: 8.982

10.  Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.

Authors:  Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-08-15       Impact factor: 4.492

View more
  1 in total

Review 1.  Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.

Authors:  Marit D Moen; Susan J Keam
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.